Please ensure Javascript is enabled for purposes of website accessibility
top of page

Preclinical Development for Personalized Therapy Using Disease-Relevant Cell Models

Monday, July 15 2024, 12:30 pm US EDT

iXCells Biotechnologies is specialized in providing innovative pre-clinical drug discovery solutions with the focus on disease-relevant cell models. We have been working with multiple rare disease advocacy groups for development of personalized therapy with different modalities (ASO, small molecule repurposing, gene therapy) in a variety of cell lines, including primary cells and patient-derived iPSC models. In this presentation, we will discuss the selection of different cell models and general design for preclinical development of personalized medicine.

Nianwei Lin received his Ph.D. in genetics from the College of Medicine at the University of Florida. He was trained with a background in apoptotic cell death using Drosophila as the genetic model. In 2011, Nianwei started his postdoctoral training at Sanford-Burnham Medical Research Institute, where he went on to study the self-renewal and differentiation control of embryonic stem cells and focused his research on long noncoding RNAs (lncRNA) mediated regulation. Nianwei joined DSRD team at Pfizer as a postdoctoral fellow in August 2014, with his work focused on effects of lysosomal dysfunction on membrane trafficking and signal transduction, as well as the

implication in toxicity, efficacy and resistance development.

In 2014, Nianwei and his business partners foundediXCells Biotechnologies, a cell biology and cell technology company dedicated to providing innovative pre-clinical drug discovery solutions with the focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate drug discovery processes. The company offers the customers access to high quality primary and iPSC derived cells, custom iPSC services, functional bioassay development and execution. The company is specialized in development of Disease-in-a-dish models with its expertise in iPSC engineering and primary cell isolation for pre-clinical applications, including toxicology testing, personalized medicine development, target-based or phenotypic screening, etc..



bottom of page